GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Family Office of America Inc (OTCPK:FOFA) » Definitions » Quality Rank

FOFA (Family Office of America) Quality Rank


View and export this data going back to 2006. Start your Free Trial

What is Family Office of America Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Family Office of America Quality Rank Related Terms

Thank you for viewing the detailed overview of Family Office of America's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Family Office of America Business Description

Traded in Other Exchanges
N/A
Address
6898 S. University Boulevard, Suite 100, Centennial, CO, USA, 80122
Family Office of America Inc is the holding company of mPathix Health, Inc. The company is focused on the development, production, and distribution of multi-modal pain management and Central Nervous System related solutions. It develops pain management products using a modality-agnostic, virtual operating model. The company is developing a product designed to address the unmet needs of patients who seek alternatives to traditional pain medications and interventions or adjunctive therapies to their current treatment regimen.
Executives
Bin Wang director 112 RICO DR. NORTH, MORGANVILLE NJ 07751